DFIB Cardiac Science (MM)

Cardiac Science Awarded Contract With Novation Group Purchasing Organization Serves 2,300 Healthcare Facilities Nationwide IRVINE, Calif., March 30 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (NASDAQ:DFIB), a leading manufacturer of automatic external defibrillators, today announced that it has been awarded a contract from Novation, the supply company of VHA Inc. and the University HealthSystem Consortium (UHC), covering Cardiac Science's patented Powerheart(R) Cardiac Rhythm Module(R) (CRM(R)) a fully-automatic therapeutic bedside monitor-defibrillator designed for medically-supervised environments such as hospitals, outpatient medical clinics and physician offices. The contract, which was established under Novation's new technology program, offers access to this innovative product to 2,300 VHA and UHC acute and non-acute healthcare facilities located throughout the United States. Powerheart CRM is the only FDA-cleared therapeutic bedside defibrillator- monitor on the market that is designed to be prophylactically attached to at-risk cardiac patients, continuously monitor their heart rhythms and when clinically appropriate, automatically and instantly provide lifesaving defibrillation therapy without the need to wait for intervention by a nurse or physician. Cardiac Science Chairman and CEO Raymond W. Cohen said, "The Novation contract provides us with access to a large group of hospitals and increases awareness of the Powerheart CRM technology among administrators and other decision makers. As clinical evidence mounts that suggests this technology may dramatically increase survival rates of at-risk cardiac patients and potentially reduce hospitalization costs, we believe that we may achieve greater penetration in the U.S. hospital market. " About Novation Based in Irving, Texas, Novation was established in January 1998 through a combination of the supply programs of VHA and UHC, two national health care alliances. Novation serves the purchasing needs of more than 2,300 members and affiliates of VHA and UHC. These organizations used Novation contracts to purchase more than $23 billion in supplies in 2004. About Cardiac Science Cardiac Science develops, manufactures and markets a complete line of Powerheart(R) brand, automated public access defibrillators (AEDs), and offers comprehensive AED/CPR training and AED program management services that facilitate successful deployments. The company makes the Powerheart(R) CRM(R), the only FDA-cleared therapeutic patient monitor that instantly and automatically treats hospitalized cardiac patients who suffer life-threatening heart rhythms. Cardiac Science also manufactures its AED products on a private label basis for other leading medical companies such as Nihon Kohden (Japan), Quinton Cardiology Systems and GE Healthcare. For more information please visit http://www.cardiacscience.com/ or call (949) 797-3800. This press release includes forward-looking statements. These statements may be identified by the use of forward-looking terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. Cardiac Science has based these forward-looking statements on the current expectations, assumptions, estimates and projections. While Cardiac Science believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control. Certain factors, including those discussed in Cardiac Sciences' Annual Report on Form 10-K for the year ended December 31, 2004, under the heading "Risk Factors," may cause the actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We do not undertake any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments. Contact: Matt Clawson (Investors), or Michael Gioffredi Len Hall (Media) Chief Marketing Officer Allen & Caron Inc Cardiac Science, Inc. (949) 474-4300 (949) 797-3800 DATASOURCE: Cardiac Science, Inc. CONTACT: Investors, Matt Clawson, , or Media, Len Hall, , both of Allen & Caron Inc, +1-949-474-4300, for Cardiac Science, Inc.; or Michael Gioffredi, Chief Marketing Officer of Cardiac Science, Inc., +1-949-797-3800, Web site: http://www.cardiacscience.com/

Copyright